Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 758,500 shares, a growth of 7.7% from the August 15th total of 704,500 shares. Currently, 1.9% of the company’s stock are sold short. Based on an average trading volume of 298,900 shares, the days-to-cover ratio is presently 2.5 days.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and set a $2.25 price target on shares of Kronos Bio in a research report on Monday, August 19th.
Get Our Latest Stock Report on KRON
Kronos Bio Stock Performance
Kronos Bio (NASDAQ:KRON – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.05. The company had revenue of $2.69 million for the quarter, compared to analysts’ expectations of $1.75 million. Kronos Bio had a negative net margin of 1,222.83% and a negative return on equity of 68.82%. As a group, sell-side analysts forecast that Kronos Bio will post -1.33 EPS for the current fiscal year.
Insiders Place Their Bets
In other Kronos Bio news, CEO Norbert W. Bischofberger acquired 410,848 shares of the company’s stock in a transaction on Thursday, June 27th. The shares were acquired at an average cost of $1.17 per share, with a total value of $480,692.16. Following the completion of the acquisition, the chief executive officer now directly owns 10,597,468 shares in the company, valued at $12,399,037.56. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 23.40% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Kronos Bio by 14.6% during the first quarter. Vanguard Group Inc. now owns 1,948,595 shares of the company’s stock valued at $2,533,000 after acquiring an additional 247,918 shares during the last quarter. Acadian Asset Management LLC grew its position in Kronos Bio by 58.8% during the second quarter. Acadian Asset Management LLC now owns 1,229,910 shares of the company’s stock valued at $1,524,000 after acquiring an additional 455,351 shares during the last quarter. Forefront Analytics LLC grew its position in Kronos Bio by 75.0% during the second quarter. Forefront Analytics LLC now owns 134,998 shares of the company’s stock valued at $167,000 after acquiring an additional 57,867 shares during the last quarter. Marquette Asset Management LLC grew its position in Kronos Bio by 19.8% during the first quarter. Marquette Asset Management LLC now owns 80,369 shares of the company’s stock valued at $104,000 after acquiring an additional 13,269 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Kronos Bio during the first quarter valued at approximately $71,000. 64.09% of the stock is currently owned by institutional investors.
About Kronos Bio
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
See Also
- Five stocks we like better than Kronos Bio
- Want to Profit on the Downtrend? Downtrends, Explained.
- Silver’s Breakout: 3 Momentum Stocks You Can’t Miss
- Consumer Staples Stocks, Explained
- Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
- Most Volatile Stocks, What Investors Need to Know
- Airline Stocks Off the Beaten Path: 3 Key Picks for Investors
Receive News & Ratings for Kronos Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kronos Bio and related companies with MarketBeat.com's FREE daily email newsletter.